Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaċċini - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

valneva sweden ab - 'tossina b tal-kolera, vibrio cholerae 01 - cholera; immunization - vaċċini - dukoral huwa indikat għall-immunizzazzjoni attiva kontra l-marda kkawżata minn vogrio cholerae serogroup o1 f'adulti u tfal minn sentejn li se jżuru żoni endemiċi / epidemiċi. l-użu ta 'dukoral għandha tiġi stabbilita fuq il-bażi ta' rakkomandazzjonijiet uffiċjali filwaqt li jitqiesu l-varjabilità tal-epidemjoloġija tal-post u r-riskju tat-teħid tal-marda f'żoni ġeografikament differenti u l-kundizzjonijiet waqt il-vjaġġ. dukoral m'għandux jissostitwixxi miżuri ta ' ħarsien standard. fil-każ ta ' dijarea-miżuri ta'rijidrattazzjoni għandhom jiġu istitwiti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drogi użati fid-dijabete - dijabete mellitus fejn huwa meħtieġ it-trattament bl-insulina. insuman rapid huwa wkoll adattat għall-kura ta 'koma ipergliċemika u ketoaċidożi, kif ukoll għall-kisba ta' stabilizzazzjoni minn qabel, intra u wara l-operazzjoni f'pazjenti bid-dijabete mellitus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, razza cvd 103-hgr, ħaj - kolera - vaċċini - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. dan il-vaċċin għandu jintuża skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amivas ireland ltd - artesunate - malarja - antiprotozoali - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu adattat ta ' aġenti antimalarial.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratorios hipra s.a - virus ħaj tal-virus tal-herpes tal-ifrat imħallat b'ġenet doppju tip 1, razza ceddel: 106.3-107.3 ccid50 - immunoloġiċi - bhejjem - għal-immunizzazzjoni attiva tal-bhejjem mill-età ta 'tliet xhur kontra l-bovini virus herpes tat-tip 1 (bohv-1) biex jitnaqqsu s-sinjali kliniċi ta' infectious bovine rhinotracheitis (ibr) u l-eskrezzjoni tal-virus fil-qasam. il-bidu tal-immunità: 21 jum wara t-tlestija tal-iskema bażika tat-tilqim. tul ta 'żmien tal-immunità: 6 xhur wara t-tkomplija tal-iskema bażika tat-tilqim.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer limited - virus ta 'l-influwenza tat-tjur inattivat rikombinanti - immunoloġiċi - chicken; ducks - għal immunizzazzjoni attiva ta 'tiġieġ u papri kontra l-virus ta' l-influwenza tat-tjur tat-tip a, sottotip h5. tiġieġ: tnaqqis tal-mortalità u l-eskrezzjoni tal-virus wara l-isfida. il-bidu tal-immunità: 3 ġimgħat wara t-tieni injezzjoni. it-tul ta 'żmien tal-immunità fit-tiġieġ għadu ma ġiex stabbilit. papri: tnaqqis ta ' sinjali kliniċi u eskrezzjoni tal-virus wara sfida. il-bidu tal-immunità: 3 ġimgħat wara t-tieni injezzjoni. tul tal-immunità fil-papri: 14-il ġimgħa wara t-tieni injezzjoni.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratorios hipra s.a. - virus ħaj inattivat tal-respiratorja bovina-virus sinktjali (brsv), razza lym-56 - immunoloġiċi għall-bovini, baqar, vaċċini virali Ħajjin, respiratorja bovina-virus sinktjali (brsv) - bhejjem - tilqim attiv ta ' baqar biex jitnaqqsu l-virus jixħtu u respiratorji is-sinjali kliniċi ikkawżati mill-respiratorja bovina-infezzjoni tal-virus sinktjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

orion corporation - entacapone - marda ta 'parkinson - mediċini kontra l-parkinson - entacapone huwa indikat bħala frozen preparazzjonijiet standard ta ' ticlopidine hydrochloride / benserazide jew ticlopidine hydrochloride / carbidopa għall-użu fil-pazjenti bil-marda ta ' parkinson's u l-tmiem tad-doża oxxillazzjonijiet vetturi bil-mutur, li ma jistax jiġi stabbilizzat fuq dawk l-għaqdiet.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - marda ta 'parkinson - sistema nervuża - ticlopidine hydrochloride/carbidopa/entacapone orion huwa indikat għall-kura tal-pazjenti adulti mal-marda ta ' parkinson's u l-tmiem tad-doża oxxillazzjonijiet vetturi bil-mutur mhux stabbilizzat fuq ticlopidine hydrochloride / dopa-decarboxylase (ddc)-inibitur trattament.